Johannes vom Berg | PI
University of Zurich

Johannes vom Berg is a group leader at the Institute of Laboratory Animal Science (LTK), University of Zurich, Switzerland since 2019. Before that his main occupation was to direct the LTK transgenic mouse core facility of the University of Zurich from 2014-2018. He studied biology and molecular medicine at University of Freiburg im Breisgau and at the Max Planck Institute for Immunobiology and Epigenetics in Freiburg, Germany with a research stay at the University of Calgary, Canada. Johannes received his PhD from the Institute of Experimental Immunology at the University of Zurich, Switzerland in 2012 where he also worked as a postdoctoral fellow before joining LTK. His main research interest is in neuroimmunology, with a focus on local combination immunotherapy of brain tumors and local delivery of biologics. A second research interest revolves around basic immunological studies towards immunotherapy of cancer for companion dogs. His laboratory combines immunology, protein and genetic engineering and various in vivo and ex vivo techniques. He is also co-founder and employee (CSO) of InCephalo Therapeutics AG, a UZH spin-off developing immunotherapy approaches for brain cancer.